1.75
-0.03(-1.69%)
Currency In USD
Address
East R&D Building
Taicang, 215400
China
Phone
86 512 5357 7866
Sector
Healthcare
Industry
Biotechnology
Employees
62
First IPO Date
March 19, 2021
Name | Title | Pay | Year Born |
Dr. Barry D. Quart Pharm.D. | Chief Executive Officer & Director | 547,466 | 1957 |
Ms. Lisa Peraza CPA | Vice President of Finance | 210,889 | 1977 |
Mr. David L. Szekeres J.D. | President | 409,305 | 1974 |
Dr. Srikanth Pendyala M.D. | Senior Vice President of Clinical Development(Consultant) | 0 | N/A |
Dr. Raul Collazo Ph.D. | Vice President & Global Head of Medical Affairs | 0 | 1967 |
Mr. Jeff Cohn J.D. | General Counsel & Corporate Secretary | 0 | 1982 |
Mr. Sean T. Ristine | Vice President of Human Resources | 0 | 1970 |
Dr. Lei Sun Ph.D. | Vice President of Biologics & Head of CMC | 0 | 1964 |
Ms. Kimberly J. Manhard | Executive Vice President & Chief Development Officer | 0 | 1960 |
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.